44 Lymphoma Clinical Trials in Houston, NC (2026)

Q: How do I join a clinical trial in Houston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you.

Recruiting Lymphoma Studies in Houston

NCT05676450Recruiting

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from ...

Houston, NC517 participantsM.D. Anderson Cancer Center

View Study Details

NCT06072131Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for...

Houston, NC504 participantsAcrotech Biopharma Inc.

View Study Details

NCT05091424Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic...

Houston, NC332 participantsHoffmann-La Roche

View Study Details

NCT06393738Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R...

Houston, NC255 participantsArvinas Inc.

View Study Details

NCT07082803Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies i...

Houston, NC180 participantsTreeline Biosciences, Inc.

View Study Details

NCT07284433Recruiting

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy use...

Houston, NC178 participantsAvenCell Therapeutics, Inc.

View Study Details

NCT06542250Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Ma...

Houston, NC174 participantsAstraZeneca

View Study Details

NCT06137144Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in p...

Houston, NC161 participantsAstraZeneca

View Study Details

NCT05169515Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL....

Houston, NC121 participantsHoffmann-La Roche

View Study Details

NCT04771572Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under ...

Houston, NC100 participantsNewave Pharmaceutical Inc

View Study Details

NCT05011045Recruiting

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help rese...

Houston, NC100 participantsM.D. Anderson Cancer Center

View Study Details

NCT06207812Recruiting

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

To follow up with all our participants with juvenile-onset mycosis fungoides, check on their status, and ask them or their parents about long term outcomes associated with their condition....

Houston, NC100 participantsM.D. Anderson Cancer Center

View Study Details

NCT05910801Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that ha...

Houston, NC100 participantsAcademic and Community Cancer Research United

View Study Details

NCT06176690Recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease...

Houston, NC90 participantsBaylor College of Medicine

View Study Details

NCT05092451Recruiting

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma...

Houston, NC80 participantsM.D. Anderson Cancer Center

View Study Details

NCT01853631Recruiting

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "...

Houston, NC64 participantsBaylor College of Medicine

View Study Details

NCT02917083Recruiting

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combi...

Houston, NC60 participantsBaylor College of Medicine

View Study Details

NCT03081910Recruiting

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. No one way seems p...

Houston, NC54 participantsBaylor College of Medicine

View Study Details

NCT04664179Recruiting

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, ...

Houston, NC52 participantsBaylor College of Medicine

View Study Details

NCT07316010Recruiting

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

The goal of the main clinical research study is to learn if treatment with a chimeric antigen receptor (CAR) T-cell therapy called lisocabtagene maraleucel (liso-cel) can help to prevent recurrence of...

Houston, NC50 participantsM.D. Anderson Cancer Center

View Study Details

NCT05929612Recruiting

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease respond...

Houston, NC50 participantsM.D. Anderson Cancer Center

View Study Details

NCT06263491Recruiting

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL....

Houston, NC50 participantsM.D. Anderson Cancer Center

View Study Details

NCT04234048Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

Houston, NC46 participantsSciTech Development, Inc.

View Study Details

NCT06213311Recruiting

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control ...

Houston, NC40 participantsM.D. Anderson Cancer Center

View Study Details

NCT06045247Recruiting

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination w...

Houston, NC40 participantsM.D. Anderson Cancer Center

View Study Details

NCT06218602Recruiting

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy...

Houston, NC40 participantsM.D. Anderson Cancer Center

View Study Details

NCT06563505Recruiting

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL....

Houston, NC36 participantsM.D. Anderson Cancer Center

View Study Details

NCT05615636Recruiting

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL....

Houston, NC36 participantsM.D. Anderson Cancer Center

View Study Details

NCT05773040Recruiting

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory....

Houston, NC33 participantsM.D. Anderson Cancer Center

View Study Details

NCT04745949Recruiting

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, ...

Houston, NC31 participantsM.D. Anderson Cancer Center

View Study Details

NCT05529069Recruiting

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to t...

Houston, NC30 participantsM.D. Anderson Cancer Center

View Study Details

NCT05464719Recruiting

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safet...

Houston, NC30 participantsM.D. Anderson Cancer Center

View Study Details

NCT06630091Recruiting

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

To learn if the study drug golidocitinib given alone or in combination with the standard drug combination therapy called CHOP can help to control PTCL....

Houston, NC30 participantsM.D. Anderson Cancer Center

View Study Details

NCT07283679Recruiting

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

The goal of this clinical research study is to learn if ONC-PluReceptor NK cell therapy (combined with the monoclonal antibody therapies epcoritamab and tafasitamab) can help to control relapsed or re...

Houston, NC30 participantsM.D. Anderson Cancer Center

View Study Details

NCT07220993Recruiting

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

Houston, NC27 participantsBaylor College of Medicine

View Study Details

NCT07586618Recruiting

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. 4A1...

Houston, NC24 participantsAllterum Therapeutics, Inc

View Study Details

NCT05967416Recruiting

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgki...

Houston, NC24 participantsSIRPant Immunotherapeutics, Inc.

View Study Details

NCT06792734Recruiting

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat r...

Houston, NC24 participantsBantam Pharmaceuticals

View Study Details

NCT05355051Recruiting

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment ...

Houston, NC24 participantsM.D. Anderson Cancer Center

View Study Details

NCT03829540Recruiting

CD4CAR for CD4+ Leukemia and Lymphoma

This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell l...

Houston, NC20 participantsHuda Salman

View Study Details

NCT06698822Recruiting

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL....

Houston, NC20 participantsM.D. Anderson Cancer Center

View Study Details

NCT06043323Recruiting

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL....

Houston, NC20 participantsM.D. Anderson Cancer Center

View Study Details

NCT04288726Recruiting

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be re...

Houston, NC18 participantsBaylor College of Medicine

View Study Details

NCT04139304Recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in tr...

Houston, NC15 participantsAIDS Malignancy Consortium

View Study Details

About Lymphoma Clinical Trials in Houston

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 44 lymphoma clinical trials recruiting participants in Houston, NC. These studies are seeking a combined 4,010 participants. Research is being sponsored by M.D. Anderson Cancer Center, Acrotech Biopharma Inc., Hoffmann-La Roche and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Houston — FAQ

Are there lymphoma clinical trials in Houston?

Yes, there are 44 lymphoma clinical trials currently recruiting in Houston, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 44 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 13, 2026 from ClinicalTrials.gov